XOMA 629

Description

XOMA 629 is a gel formulation of a synthetic peptide derived from bactericidal/permeability-increasing protein (BPI), a human host-defense protein that is one of the body’s early lines of defense against invading microorganisms. We are currently evaluating XOMA 629 for the topical eradication of infectious pathogens including Staphylococcus aureus (S. aureus), both methicillin-sensitive S. aureus (MSSA), and the common skin infection, impetigo.

Our unique topical treatment for skin infections, XOMA 629, is a gel formulation of a synthetic peptide derived from a human host-defense protein. XOMA 629 is currently under evaluation in a Phase 2A study in patients with the common skin infection, impetigo. Additional studies of XOMA 629 are planned for the topical eradication of infectious pathogens including Staphylococcus aureus (S. aureus) and methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA).

Along with an alarming rise in antibiotic resistance, treatment of topical bacterial infections has become more complex. In preclinical studies, XOMA 629 has been shown to act as a broad-spectrum antimicrobial compound. XOMA 629 has an encouraging safety profile based on clinical experience in approximately 300 patients.

Publications and Presentations

"XMP.629, a Peptide Derived From Functional Domain II of BPI, Demonstrates Broad-Spectrum Antimicrobial and Endotoxin-Neutralizing Properties In Vitro and In Vivo" (PDF), Edward Lim, et al., International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001.